JADE: Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis
Study Details
Study Description
Brief Summary
Dermatomyositis (DM) are rare and heterogeneous systemic autoimmune diseases, characterized by the association of muscle inflammation, skin inflammation and vasculopathy. DM concern both adults and children. DM can be life-threatening (interstitial lung disease, infectious complications) and responsible of significant functional disability (muscle weakness). Age of onset appear to be an independent prognostic factor. Juvenile-onset DM is characterized by a higher frequency of calcinosis, skin ulceration and digestive vasculitis. In adults, interstitial lung disease and cancer are more frequent with higher mortality. Data concerning the comparison of the initial severity between juvenile and adult-onset DM are limited.
The main objective is to compare global severity between juvenile DM and adult-onset DM at initial diagnosis.
Secondary objectives are:
-
to compare organ-specific severity between juvenile DM and adult-onset DM at diagnosis.
-
to compare damage during follow-up and at last follow-up between juvenile DM and adult-onset DM.
-
to compare activity at the last follow-up between juvenile DM and adult-onset DM.
-
to compare iatrogenic complications between juvenile DM and adult-onset DM.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Juvenile dermatomyositis Dermatomyositis before 18 years-old |
Other: evaluation of clinical severity
evaluation of clinical severity
|
| Adult-onset dermatomyositis Dermatomyositis from 18 years-old |
Other: evaluation of clinical severity
evaluation of clinical severity
|
Outcome Measures
Primary Outcome Measures
- number of patients with global severity [baseline (J0)]
presence of at least one criteria among: severe muscle disease (Childhood Myositis Assessment Scale - CMAS - score < 15, and/or Manual Muscle Testing 8 - MMT8 - score < 30, and/or Medical Research Council - MRC - muscle testing < 3, and/or dysphagia and/or swallowing difficulties), symptomatic interstitial lung disease (ILD), digestive vasculitis (digestive bleeding and/or vasculitis on CT-scan), myocarditis on cardiac MRI, severe skin ulcerations, intensive care unit admission
Secondary Outcome Measures
- number of patients with muscular severity [baseline (J0)]
presence of at least one of the following criteria: CMAS score < 15, MMT8 score < 30, MRC muscle testing < 3, dysphagia, swallowing difficulties
- number of patients with pulmonary severity [baseline (J0)]
presence of symptomatic ILD
- number of patients with digestive severity [baseline (J0)]
presence of digestive vasculitis: digestive bleeding and/or vasculitis on CT-scan
- number of patients with cutaneous severity [baseline (J0)]
presence of severe skin ulcerations
- myositis damage index (MDI) score [2 years of follow-up, at 5 years of follow-up and at last follow-up]
myositis damage index (MDI) extent of damage score: from 0 (better outcome) to 38 (worse outcome)
- number of patients with remission at last follow-up [up to 10 years]
absence of disease activity without any immunosuppressive/immunomodulatory treatment for at least 2 years
- number of patients with disease activity at last follow-up [up to 10 years]
presence of at least one of the following criteria: elevated creatinine kinase (CK) level and/or recent muscle testing deterioration and/or muscle inflammation on MRI, and/or skin manifestations and/or progressive ILD
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patient with dermatomyositis according to 2017 American College of Rheumatology (ACR)/ European Alliance of Associations for Rheumatology (EULAR) classification
Exclusion Criteria:
-
Patient with cancer-associated dermatomyositis (within 3 years before or after diagnosis of dermatomyositis)
-
Patient with antisynthetase syndrome
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Central Hospital, Nancy, France
Investigators
- Principal Investigator: Paul Decker, MD, CHU Nancy
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2023PI150